TEVA (Teva Pharmaceuticals) Quarterly EPS earnings growth

Corporate emblem and logo of Teva Pharma (TEVA)

Teva Pharmaceutical Industries (TEVA) scalability is based on the mass production of affordable generic drugs without the costs associated with discovering new molecules. The quarterly shift in earnings per share visualizes this efficiency, while the -47.30 metric confirms the current level of operational power. Its status as a generics leader with in-house active pharmaceutical ingredient synthesis reduces costs, while expansion into biosimilars and neurology broadens its global patient reach.

Teva Pharmaceutical Industries Limited (TEVA) - Year-over-year net earnings per share change for the last twelve months from 07/04/2022 to 11/18/2026

Metric breakdowns and analytics for Teva Pharmaceuticals (TEVA)

Fundamental company valuation:tevapharm.com - TEVA
Flagship merchandise of Teva

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. This metric assesses capital generation efficiency and business scaling rates. By analyzing quarterly earnings per share dynamics, an investor determines the sustainability of the issuer's revenues. For Teva Pharmaceutical Industries (TEVA), this indicator confirms the success of its debt reduction strategy. Stabilized management and the development of the proprietary drug portfolio provide positive momentum for the metric.